#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Castleman's disease PIK3CA related overgrowth spectrum Cystic fibrosis gastrointestinal disease Epidermolysis bullosa Idiopathic pulmonary fibrosis Growth hormone deficiency Sickle cell anaemia Pouchitis Leiomyosarcoma Granulomatosis with polyangiitis Retinoblastoma Anti-HLA antibody test positive Neurofibroma Peripheral T-cell lymphoma unspecified Adenocarcinoma gastric More trials…

    Learn about Rare Diseases

    Cytokine release syndrome – Diagnostics Glomerulonephritis membranoproliferative – Basic Information Hairy cell leukaemia recurrent Antithrombin III deficiency Malignant fibrous histiocytoma – Diagnostics Pleomorphic leiomyosarcoma – Diagnostics Primary immunodeficiency syndrome – Diagnostics Chronic granulomatous disease – Treatment Short-bowel syndrome – Treatment Basal cell naevus syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dabrafenib Folic Acid ACETYLCARNITINE HYDROCHLORIDE PROMESTRIENE Bt8009 KETOROLAC TROMETAMOL Elranatamab Thiamine Nitrate Ascorbic Acid Leriglitazone Sot102 Acou085 L-Tyrosine Dazucorilant Parsaclisib Hydrochloride Ds-3939A Sodium Sulfate Anhydrous Pegenzileukin 4-IODOPHENYLALANINE I-131 Magnesium Sulfate More therapies…

    Learn about Your Condition

    Cholangitis sclerosing Autoimmune uveitis Psychological trauma Peripheral artery angioplasty Osteoarthritis Abdominal pain Pleural mesothelioma malignant Hand dermatitis Growth hormone deficiency Mastocytosis Rhabdomyosarcoma recurrent Trigeminal neuralgia Erosive oesophagitis Embolism venous Erectile dysfunction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer recurrent

  • A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    Investigated Drugs:
    • Pemetrexed Disodium
    • BNT327
    • Carboplatin
    Germany Italy Poland Spain

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Ipilimumab
    France Greece Italy Poland Romania

  • Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer stage IV
    • Non-small cell lung cancer
    Investigated Drugs:
    • Relatlimab
    • Pemetrexed Disodium
    • Carboplatin
    Austria Belgium Denmark France Germany Ireland +6

  • Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Taletrectinib
    France Italy Poland Spain

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Biliary cancer metastatic
    • Breast cancer recurrent
    • Breast cancer stage IV
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!